Connect with us

Biotech

ADmit Therapeutics Closes 4.2M Round to Launch its Alzheimer’s Test

In the short term, the early detection test developed by ADmit Therapeutics will make it possible to optimize patient recruitment for clinical trials. People will be selected in an optimal way, which will increase the possibility of identifying a curative drug by demonstrating its efficacy and helping pharmaceutical companies to make progress in the fight against this type of dementia.

Published

on

ADmit Therapeutics continues to make progress against Alzheimer’s disease. The Spanish company, a spin-off of the Bellvitge Biomedical Research Institute (Idibell), has closed a €4.2 million financing round to launch its early diagnosis test against Alzheimer’s disease on the market in 2023, according to Marta Barrachina, CEO of ADmit Therapeutics.

The company was selected in 2020 by the European Commission under its EIC Accelerator funding programs to receive 3.3 million euros. The rest of the investment comes from Equality4Good, Ship2B’s social impact investment vehicle; Banc Sabadell’s BStartup; Wa4steam, an international association of women business angels; Genesis Biomed, a biomedical sector consultancy; Capital Cell, an equity crowdfunding platform specializing in biomedicine; and other investors. ADmit Therapeutics has also received public funding from EIT Health, the Center for the Development of Industrial Technology (Cdti) and the Ministry of Science and Innovation.

The main objective of ADmit Therapeutics is to develop and commercialize for clinical practice an early diagnostic test that will allow, through a blood test, to detect Alzheimer’s disease in those patients with the first memory complaints.

Read more about ADmit Therapeutics Alzheimer’s test and find the most important business headlines with the Born2Invest mobile app. Download our companion app for free and stay on top of the markets.

ADmit Therapeutics expects to launch its test on the market next year

The test represents the determination of a series of proprietary biomarkers, not related to the protein that accumulates in the brain β-amyloid or tau. ADmit Therapeutics’ value proposition is based on an epigenetic analysis in blood, covering a large number of methylcytosines using next-generation sequencing techniques.

SEE ALSO  Creative ways to promote your startup for free

Given that mitochondrial dysfunction has been described at the systemic level prior to the appearance of β-amyloid ni tau brain aggregates, “the patented biomarkers may represent a very useful tool for early detection of Alzheimer’s patients in early stages of the disease and improve their quality of life,” Barrachina explained.

In the short term, the early detection test developed by ADmit Therapeutics will make it possible to optimize patient recruitment for clinical trials. People will be selected in an optimal way, which will increase the possibility of identifying a curative drug by demonstrating its efficacy and helping pharmaceutical companies to make progress in the fight against this type of dementia.

“In any disease, the earlier the problem is detected the better, but even more so in the case of Alzheimer’s, because you can be more than twenty years with the disease without having any symptoms,” explained the CEO of ADmit Therapeutics. “The most important problem is that, during this time, the neurons in the brain are dying and when the diagnosis arrives it is too late to repair the damaged tissues,” she remarked.

ADmit Therapeutics is a company that was born in 2017 and was created by Marta Barrachina, in addition to Ramón Reñe, doctor and former head of the Functional Unit of Dementias at Bellvitge University Hospital, and Jordi Gascón, neurologist specializing in dementias, section head of the Neurology Service and coordinator of the Functional Unit of Dementias at Bellvitge University Hospital.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Arturo Garcia started out as a political writer for a local newspaper in Peru, before covering big-league sports for national broadsheets. Eventually he began writing about innovative tech and business trends, which let him travel all over North and South America. Currently he is exploring the world of Bitcoin and cannabis, two hot commodities which he believes are poised to change history.